The present study aims to evaluate the synergistic activity of nicotinic acid (NIC) with the Imipenem (IMI) as an anti-biofilm for clinical isolated Pseudomonas aeruginosa. The values of minimum inhibitor concentration (MICs) for IMI and NIC (Separately) against P. aeruginosa were (16) ug/mL and (8) ug/ml respectively. Whereas, the concentration of NIC with IMI (as combined) for biofilm inhibition was 1 ug/ml for NIC and 4 ug/ml for IMI. The combining of NIC with IMI showed synergistic efficacy against formation of bacterial biofilm (at MIC levels). These results provide a conclusion that NIC combined with IMI is can be considered as a successful prospective treatment against the biofilm produced by P. aeruginosa and as antibacterial medication.
A recurrent condition that affects up to 10% of people worldwide is gastric ulceration illness. The existence of gastric juice pH with the lowering of mucous defences is prerequisites for the development of chronic ulcers. The main variables affecting the mucosa susceptibility to damage include Helicobacter pylori (H. pylori) infections or non-steroidal anti-inflammatory medicines (NSAIDs). Proton pump inhibitors (PPIs) including histamine-2 (H2) receptor inhibitors, two common therapies for peptic ulcers, have been linked to side impacts, recurrence or a variety of pharmacological combinations. Conversely, therapeutic herbs or the chemicals they contain may be used to cure or eliminate a wide range of illnesses. Therefore, prominent pharma
... Show More